Expression of N-cadherin in myocardial tissues during the development of a rat heart.

We investigated the expression and distribution of N-cadherin during the development of a rat heart. Immunohistochemistry (IHC) was performed to detect the expression and distribution of N-cadherin in the myocardial tissues of rats at embryonic day 18 (E18d), postnatal day 5 (P5d), postnatal day 19 (P19d), postnatal day 40 (P40d), and postnatal year 1 (P1y). Reverse transcription polymerase chain reaction was used to determine mRNA expression levels of N-cadherin in the myocardial tissues at E18d, P5d, P19d, P40d, and P1y. The IHC results showed that at E18d N-cadherin was dispersedly distributed both on the cell surface and in the cytoplasm of the myocardial cells, and gradually became concentrated at the end-to-end intercalated discs of the cardiomyocytes from birth through immaturity. In the young, middle-aged, and old rats, N-cadherin was typically distributed at the intercalated discs at the end of the myocardial cells. No significant differences in the mRNA expression levels of N-cadherin were detected in the myocardial tissue of rats at E18d, P5d, P19d, P40d, and P1y. During the development of the rat heart, observable changes in the distribution of N-cadherin occurred in the myocardial tissues, but there were no detectable changes in the expression of N-cadherin, indicating that N-cadherin is indispensable to maintaining the physical structure and function of the heart.

Treatment of silicosis with hepatocyte growth factor-modified autologous bone marrow stromal cells: a non-randomized study with follow-up.

Pulmonary silicosis is an irreversible and untreatable disease that is characterized by interstitial lesions and perpetual fibrosis in the lungs. This study was performed to determine whether mesenchymal stem cells (MSCs) and hepatocyte growth factor (HGF) could exhibit therapeutic effects on human silicosis. This non-randomized uncontrolled trial comprised four patients with pulmonary silicosis who had developed lung fibrosis and received autologous bone marrow MSCs previously transfected by a vector containing human HGF cDNA (MSCs/HGF). MSCs/HGF were intravenously administered weekly for three consecutive weeks at a dose of 2 x 10(6) cells/kg. Pulmonary function, high kilo-voltage chest X-ray radiography, computed tomography (CT) scan, and peripheral blood lymphocyte subset and serum IgG concentrations were evaluated after cell therapy. The treatment was found to be generally safe. Symptoms such as cough and chest distress gradually ameliorated at six months post-therapy, accompanied by the significant improvement of pulmonary function. The ratios of the peripheral CD4- and CD8- positive cell concentrations were increased (P < 0.05). Furthermore, the serum IgG levels in these patients were decreased and reached the normal range (P < 0.05). CT scans showed partial absorption of the nodular and reticulonodular lesions in the lungs during follow-up of at least 12 months. The effectiveness of this novel regimen observed in these patients suggests that a placebo-controlled clinical trial needs to be developed. This study carries trial registration No. NCT01977131 (ClinicalTrials.gov).

Evaluation of three different promoters driving gene expression in developing chicken embryo by using in vivo electroporation.

To investigate the variance of exogenous gene expression driven by different promoters by in vivo electroporation, 3 plasmid vectors carrying different promoters were selected, and their driving strength was compared in developing chicken embryos. The 3 promoters included: 1) the CAG promoter (containing the cytomegalovirus (CMV) immediate early enhancer and the chicken ß-actin promoter), 2) the CMV promoter (the human CMV immediate early region enhancer), and 3) the SV40 promoter (Simian virus 40). The intensity of GFP expression driven by the 3 promoters was detected by fluorescence microscopy. The results clearly showed that the expression intensity of the reporter gene differed significantly among the 3 promoters. Chicken ß-actin promoter induced the highest intensity of GFP expression, while SV40 promoter induced the lowest intensity. Our results indicate that plasmids with appropriate promoters should be carefully selected to obtain strong exogenous gene expression by in vivo electroporation.